Kirjojen hintavertailu. Mukana 12 657 676 kirjaa ja 12 kauppaa.

Kirjailija

Tushar Bambharoliya

Kirjat ja teokset yhdessä paikassa: 2 kirjaa, julkaisuja vuosilta 2020-2024, suosituimpien joukossa Collagen-Based Biotextiles for Tissue Engineering. Vertaile teosten hintoja ja tarkista saatavuus suomalaisista kirjakaupoista.

2 kirjaa

Kirjojen julkaisuhaarukka 2020-2024.

Collagen-Based Biotextiles for Tissue Engineering

Collagen-Based Biotextiles for Tissue Engineering

Fan Zhang; Daxian Zha; Yihan Huang; Monica Vijay Deshpande; Ting He; Jiyang Chen; Tushar Bambharoliya; Martin W. King

Springer International Publishing AG
2024
sidottu
Based on the author's extensive research experience in collagen textiles and tissue engineering, this book presents a comprehensive introduction and guidelines for engineering artificial tissue using collagen-based fibrous material as a therapeutic candidate for regenerative medicine. The book covers different aspects of fibrous collagen material, including its chemistry, sourcing, fabrication, and applications in tissue engineering and regenerative medicine. Collagen-Based Biotextiles for Tissue Engineering provides a state-of-the-art overview of fibrous collagen-based materials and their application in tissue engineering and regenerative medicine for academic researchers, material scientists, and bioengineers.
Coronary Artery Disease and The Evolution of Angioplasty Devices

Coronary Artery Disease and The Evolution of Angioplasty Devices

Martin W. King; Tushar Bambharoliya; Harshini Ramakrishna; Fan Zhang

Springer Nature Switzerland AG
2020
nidottu
In this concise but authoritative book, the authors take the reader through the epidemiology, risk factors and the basic mechanism of coronary artery disease. In addition, they explain how coronary microvascular dysfunction can lead to angina, even after successful angioplasty following a heart attack. The methods for diagnosis and the options for treatment are explained, ending with a discussion of the evolution of coronary angioplasty from balloon catheters to novel, fully resorbable polymeric drug eluting stents. Enclosed is a list of currently available commercial devices, as well as a listing of experimental products under research and development, so that readers can appreciate the serious nature of this disease and have an understanding of how the medical device sector is attempting to address this major healthcare problem. Globally in 2010, ischemic heart disease was the cause of 13.3% of all deaths. In the US alone, the direct medical costs from coronary artery disease andstroke are currently estimated to be $126 billion per year, and are expected to rise to $309 billion by 2035.